Ozempic risks and off-label use: what the evidence shows

What did @samwardsays actually say?

The creator argues that Ozempic was designed exclusively for type 2 diabetes, that social media drove mass off-label weight loss use, and that this off-label use is now fueling lawsuits over stomach paralysis, intestinal blockages, and persistent vomiting. They cite the Financial Express as a source and claim the FDA forced a label update in 2023 to address these risks. The throughline is that people using it for weight loss "were never warned of the risks."

The creator also states that "millions of people around the world are using it for weight loss" outside its tested medical purpose, framing this as the root cause of the litigation. It's a reasonable editorial angle, but several of the specific claims deserve a closer look.

Does the science back this up?

Partially, but the framing has real holes in it. Semaglutide was indeed approved first for type 2 diabetes (Ozempic, 2017), but the same active molecule was later approved specifically for chronic weight management under the brand name Wegovy in 2021. Calling weight loss use "outside its tested medical purpose" ignores a large clinical trial program. The STEP trials (Wilding et al., 2021, NEJM) enrolled adults with obesity but without diabetes and showed around 15% body weight reduction. The drug has been extensively tested in people who are not diabetic.

On the lawsuit claims: gastroparesis and ileus are real, documented adverse events. A 2023 case series published in JAMA (Sodhi et al., 2023) found GLP-1 receptor agonists were associated with increased risk of gastroparesis compared to bupropion-naltrexone. That's real signal. But the creator conflates the existence of lawsuits with proven causation, which is legally and scientifically a different standard.

What did they get wrong (or right)?

They got the FDA label update roughly right. The FDA did add a gastroparesis warning to semaglutide labeling, and intestinal obstruction is listed as an adverse reaction in prescribing information updated in 2023. Credit where it's due.

What they got wrong is the claim that people were "never warned of the risks if they weren't diabetic." Wegovy's prescribing information, approved for non-diabetic obesity patients, includes gastrointestinal side effect warnings. Anyone prescribed Wegovy off-label or on-label should have received informed consent covering these risks. The creator also leans on the Financial Express, a general financial news outlet, as a primary source for medical risk claims. That's a credibility problem. Primary sources exist and are publicly accessible.

The phrase "drug's popularity as a weight loss hack" is editorially loaded. Treating obesity as a metabolic disease with pharmaceutical options is not a hack. The American Diabetes Association and Obesity Society both classify obesity as a chronic disease. Framing semaglutide use for obesity as inherently suspect misrepresents the clinical evidence.

What should you actually know?

If you're considering a GLP-1 receptor agonist for weight management, the distinction between Ozempic and Wegovy matters. Ozempic is FDA-approved for type 2 diabetes. Wegovy contains the same molecule (semaglutide) at a higher dose and is FDA-approved specifically for chronic weight management in adults with a BMI of 30 or above, or 27 with a weight-related condition. Using Ozempic off-label for weight loss is common, but Wegovy exists precisely because the evidence supported a separate indication.

Gastrointestinal side effects are real and documented. Nausea affects roughly 44% of patients in clinical trials (Wilding et al., 2021, NEJM). Gastroparesis is rarer but has been reported. Patients should discuss their full medical history, including any prior gastrointestinal conditions, with a licensed prescriber before starting any GLP-1 therapy. The lawsuits are active litigation, not settled science, and conflating the two misleads viewers about what is actually known.

• Semaglutide (Wegovy) has been studied in non-diabetic adults with obesity in large randomized controlled trials.
• GLP-1 receptor agonists carry documented GI risks including nausea, vomiting, and rare cases of gastroparesis.
• The FDA label update in 2023 is real. Consulting your prescriber about these risks is the appropriate response, not avoiding treatment.

Bottom line

This video raises legitimate concerns about GLP-1 safety but packages them with shaky sourcing and misleading framing. The creator is right that side effects are real and that the FDA updated labeling. They're wrong to imply weight loss use has no clinical basis, and wrong to suggest non-diabetic users were categorically never warned. The science is genuinely complex. Oversimplifying it into a "dangerous shortcut" narrative does viewers a disservice.